Kenvue has launched a secondary underwritten public offering involving 182,329,550 shares of its common stock. Notably, Kenvue itself isn’t parting with any shares of common stock in this offering and won’t be benefiting from proceeds generated by the sale of the Shares in the Offering or from the debt-for-equity exchange detailed below.
As part of the Offering, Johnson & Johnson is anticipated to swap 182,329,550 shares of Kenvue’s common stock for debts owed by Johnson & Johnson to Goldman Sachs & Co. LLC and J.P. Morgan. Subsequently, upon completion of the debt-for-equity exchange, if finalized, the Selling Shareholders plan to sell the Shares to the underwriters involved in the Offering. Following the Offering, Johnson & Johnson will no longer retain any ownership of Kenvue’s common stock.
Goldman Sachs & Co. LLC, J.P. Morgan, and BofA Securities are jointly serving as lead book-running managers for the Offering.
J&J completed the most significant transformation in its 137-year existence, redirecting its attention towards its pharmaceutical and medical devices divisions. In May of the previous year, the corporation sold 172.8 million shares in Kenvue, raising $3.8 billion, subsequently reducing its ownership stake over the ensuing three months.
Since the spinoff, Kenvue has concentrated on its 15 priority brands and recently announced intentions to reduce its global workforce by 4%. Kenvue Net sales for the first quarter of 2024 increased by 1.1% to $3.9 billion, building upon a 7.3% increase in the corresponding period of the previous year. Organic growth, which reached 1.9%. This growth was mainly fueled by sustained consumer demand in Self Care and growth in Essential Health, particularly in Oral Care, although Skin Health and Beauty segments performed below expectations.
The rise in net sales and organic growth was primarily fueled by robust performance in Self Care and Essential Health sectors, driven by significant consumer demand in Self Care and growth in Essential Health, particularly in Oral Care. However, these achievements were partially dampened by weaker performance in the Skin Health and Beauty categories.
During the first quarter, Kenvue witnessed a gross profit margin of 57.6%, marking an increase from 55.2% in the corresponding period of the previous year. The adjusted gross profit margin reached 60.2%, compared to 57.3% in the previous year’s period. This expansion, totaling 240 basis points in gross profit margin and 290 basis points in adjusted gross profit margin, was primarily attributed to value realization, continuous efficiency enhancements in the global supply chain, and a decline in net input cost inflation.
Nevertheless, the operating income margin for the first quarter was 14.1%, down from 16.6% in the prior year period. This decline was largely due to a $68 million impairment charge associated with the company’s interim headquarters and expenses related to restructuring and optimization endeavors.
Net sales and organic growth were influenced by a 5.0% increase in value realization, offset by a 3.1% decrease in volume. In the first quarter, diluted earnings per share amounted to $0.15, while adjusted diluted earnings per share were $0.28.
